Drug intelligence / Profile preview

Diena Pharbil

Development stage: Unknown
Lead developer: PHARBIL Pharma
Modality: Small Molecules
Administration: Oral

Overview

Diena Pharbil is a combined oral contraceptive developed by Pharbil Waltrop GmbH, containing 0.03 mg of ethinylestradiol and 2 mg of dienogest. As a combined hormonal contraceptive, it functions by suppressing the secretion of gonadotropins (FSH and LH), which prevents ovulation. Additionally, it alters the cervical mucus to inhibit sperm penetration and modifies the endometrium to reduce the likelihood of implantation. It was developed as an immediate-release formulation bioequivalent to the reference product Valette. The drug is currently reported as discontinued or out of distribution in its primary markets.

Brand names: Diena PharbilDienaEthinylestradiol/Dienogest Pharbil Waltrop
Other names: ethinylestradiol + dienogest

Targets

ER (Estrogen receptor)PR (Progesterone receptor)

Beyond the preview

Go deeper on Diena Pharbil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diena Pharbil.

Explore the full profile